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Objectives . This study was undertaken to establish evidence for
physiologic activity and to study the safety of murine-derived
monoclonal antibody 7E3 Fab (m7E3 Fab) in patients receiving
recombinant tissue.type plastninogen activator (rt-PA) .
ackground. Platelet aggregation is believed to be a significant
factor in the failure of pharmacologic reperfusion . y binding to
the glycoprotein fib/Ilia receptor, m7E3 Fab inhibits platelet
aggregation and has been shown experimentally to decrease the
time required for lysis and to prevent reocclusion . However, the
safety of profound platelet inhibition after thrombolysis for acute
myocardial infarction has not been tested in humans.
Methods.
Sixty patients receiving rt-PA, aspirin and heparin
for acute myocardial infarction received m7E3 Fab bolus injec-
tions in ascending doses at 3, 6 and 15 h after initiation of the
thrombolytic infusion . Ten patients treated with rt-PA but not
m7E3 Fab were studied as control subjects .
Results. Receptor site blockade and inhibition of platelet
Although thrombolytic therapy has become the standard of
care for patients with acute myocardial infarction over the
past 7 years, postthrombolytic ischemia, reinfarction and
reocclusion of the infarct-related artery remain significant
problems. After thrombolysis with current standard regi-
mens, the infarct-related vessel remains unstable ; >20% of
patients exhibit clinical signs of recurrent ischemia within
the first few days after receiving therapy (1), and angio-
graphic reocclusion ultimately occurs in as many as 30%
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aggregation to 20 pmollfiter adenosine diphosphate were maximal
at a dose of 0.25 mg/kg body weight of m7E3 Fab . Fifteen (25%)
m7E3 Fab-treated patients and five (50%) control patients had
major bleeding; eight of these events in seven m7E3 Fab-treated
patients and one In a control patient occurred at the time of
aortocoronary bypass surgery . Recurrent ischemia occurred in
eight (13%) m7E3 Fab-treated patients and two (20%) control
subjects. Coronary angiography was performed in 43 patients ; the
infarct-related coronary artery was patent in 5 of 9 (56%) control
patients and 34 (92%) of 37 patients receiving m7E3 Fab .
Conclusions . Profound inhibition of platelet aggregation after
thrombolysis was associated with bleeding rates comparable to
those in control patients and a low rate of recurrent ischemia
. The
combination of m7E3 Fab and rt-PA, heparlo and aspirin appears
to be a promising and safe combination that should be evaluated
in father studies of patients with acute myocardial infarction.
(J Am Call Cardiol 1993 ;1.2 :381-9)
(2,3) . Patients who sustain reocclusion of a previously reper-
fused artery often suffer necrosis that was initially averted
by reperfusion and they are approximately twice as likely to
die as are patients in whom reocclusion does not occur (2) .
Autopsy, experimental and clinical data implicate platelet
thrombus formation as a major contributor to both the failure
of thrombolysis and the pathogenesis of reocclusion (4-8) .
In the Second International Study of Infarct Survival (ISIS-
2), the platelet-inhibiting drug aspirin reduced both reinfarc-
tion and mortality (9). In experimental models of reperfu-
sion, several more powerful inhibitors of platelet aggregation
have been shown to accelerate the rate of lysis and to
prevent reocclusion (6,7,10-12); however, concern exists
about the safety of combining potent platelet-inhibiting
agents with thrombolytic therapy, particularly with respect
to the risk of bleeding .
The glycoproteirn (GP) Ilb1IIIa is a platelet integrin recep-
tor that on platelet activation binds soluble fibrinogen, von
Willebrand factor, and other adhesive proteins that mediate
0735.109w931$6
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platelet aggregation (13,14) . The monoclonal antibody 7E3
binds specifically to GPIIb1IIIa and inhibits platelet aggrega-
tion in a dose-dependent fashion (13,15). In animal models,
F(ab')2 and Fab fragments of 7E3 and peptide inhibitors of
GPlIbIfa accelerate recombinant tissue-type plasminogen
activator (rt-PA)-induced thrombolysis and prevent reocclu-
sion (10-12,16) . This trial was undertaken to establish evi-
dence for physiologic activity and to study the safety of
murine-derived monoclonal antibody 7E3 Fab (m7E3 Fab) in
patients receiving rt-PA for acute myocardial infarction .
Methods
Study design. The study was designed as a dose escala-
tion and timing trial and was performed at six centers . The
study protocol was approved by the Institutional Review
oard at each center, and all participating patients gave
informed consent. Patients were eligible for enrollment if
they were between age 18 and 76 years, had sudden onset of
chest pain clinically consistent with coronary ischemia un-
responsive to standard sublingual nitroglycerin and on
electrocardiogram (ECG) manifested ST segment elevation
4.1 mV in two contiguous leads or, in the presence of left
bundle branch block, had primary ST segment changes in the
inferior or anterior leads . The onset of chest pain was to
have occurred within 6 h of the time at which treatment was
begun. Patients were not eligible for enrollment if they had
one of the following contraindications: history of a signifi-
cant bleeding diathesis ; history of gastrointestinal or genito-
urinary bleeding within the preceding 6 weeks ; documented
stroke in the past 2 years ; major surgery during the preced-
ing 6 weeks; uncontrolled hypzi,°nsion (diastolic blood
pressure 2t110 mm Hg or systolic blood pressure
_? 180 mm Hg after treatment for chest pain) ; other advanced
illness likely to alter the prognosis ; prolonged (>10 min)
cardiopulmonary resuscitation within the preceding 2 weeks ;
severe trauma within the preceding 6 months ; psychologic or
physical inability to participate ; childbearing potential; pre-
vious splenectomy ; history of vasculitis; percutaneous trans-
luminal coronary angioplasty between the time of adminis-
tration of rt-PA and the time at which m7E3 Fab was
scheduled to be given ; previous exposure to murine mono-
clonal antibodies or known hypersensitivity to murine pro-
teins .
All patients were treated with 100 mg of rt-PA (Activase,
Genentech), given as 60 mg in the 1st b (10% of the 1st-h
dose as a bolus) and 20 mg for each of the subseque t 2 h . In
addition, patients received aspirin (160 to 325 mg/day), given
as soon as possible . In the control patients and in those
receiving m7E3 Fab at 15 h after rt-PA, heparin wt s given as
a 5,000-U bolus, followed by an infusion of 1,000 U/h
beginning 90 min after the initiation of rt-PA therapy . In
patients receiving m7E3 Fab at 3 and 6 h after rt-PA, heparin
was given as a 2,500-U bolus, followed by an infusion begun
at 8'30 U/h beginning at the completion of rt-PA infusion .
Activated partial thromboplastin times were maintained at
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Table 1 . Dosing Schedule After the Start of rt-PA Infusion*
Hours After
M70 Fab Dose (mglkg)
Start of rt- 0 .10 0.15 0.20 0.25 Total
PA Infusion (n = 5) (n = 13) (n = 22) (n = 20) (n = 60)
15 5 5 12 10 32
6 4 5 5 14
3
4 5
5 14
"Ten additional patients serving as a control group did not receive m7E3
Fab but received rt-PA, aspirin and heparin in doses identical to those
receiving m7E3 Fab at the 15-h interval . Data indicate number of patients.
rt-PA = recombinant tissue-type plasminogen activator.
65 to 80 s, using a bedside monitor (Ciba Corning 512).
eta-adrenergic blocking agent therapy with intravenous
metoprolol (15 mg in three divided doses) was given to all
patients unless a contraindication was present . Routine
therapy with nitrates, morphine and oxygen was adminis-
tered as necessary .
In the initial trial design, 0 .20 mg/kg body weight of m7E3
Fab was to be administered as a bolus 15 h after the
beginning of the rt-PA infusion, however, two of the first
four patients who received this treatment developed pro-
found but transient thrombocytopenia . The trial was tempo-
rarily suspended, and in vitro studies were conducted to
assess possible causes of the thrombocytopenia . No inter-
actions between m7E3 Fab and aspirin or heparin were
identified that would enhance platelet clearance or lead to in
vivo aggregation. Particulates (protein microaggregates)
were noted in the m7E3 Fab vials used to treat these
patients, and similar particulates could be induced into the
m7E3 Fab solution by vigorous mechanical shaking or other
physical manipulation of the antibody preparation .
efore resumption of the trial, two precautionary mea-
sures were taken. First, immediately before administration,
the antibody solution was filtered through a 0 .22-µm low-
protein-binding filter (Millipore) to eliminate any particulate
matter that may have been present in the antibody solution .
Second, the dosing schedule was modified so as to start with
0.10 mglkg (Table 1). A total of 32 patients received escalat-
ing doses of m7E3 Fab at 15 h from the initiation of rt-PA .
Fourteen patients iben received escalating doses of m7E3
Fab at 6 h after the initiation of rt-PA, and 14 more patients
received escalating doses of m7E3 Fab 3 h after the initiation
of rl-PA. Patient enrollment was separated by a minimum of
24 h, and enrollment in each dosing group was separated by
72 h to allow evaluation of collected data . In addition, 10
control patients were also entered, largely during the period
when thee active treatment phase was suspended. These
patients received rt-PA, aspirin and heparin in doses identi-
cal to those used in the patients receiving m7E3 Fab at the
15-h interval
; however they did not receive m7E3 Fab.
Clinical monitoring. Patients underwent physical exami-
nation, including neurologic examination, twice daily . All
stool and urine specimens were tested for occult blood .
Coronary angiography and revascularization were per-
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formed if clinically indicated . The location of the infarct-
related vessel and Thrombolysis in Myocardial Infarction
(TIMI) flow grade (l7) were determined at the clinical
centers . Recurrent ischemia was defined as the presence of
rest angina with ECC changes, reinfarction, the need for
urgent intervention (intraaortic balloon pump, coronary an-
gioplasty, coronary artery bypass surgery) or death .
Laboratory monitoring . lood samples for platelet
counts were drawn into tubes containing ethylenediamine-
tetraacetic acid (EDTA) at baseline before treatment with
m7E3 Fab was initiated and at the following time intervals
after the administration of the m7E3 Fab bolus : 30 min and
1, 2, 6, 12, 24 and 48 h and before discharge . Hemoglobin
and hematocrit were determined at baseline and at 24 and
48 h. Prothrombin and activated partial thromboplastin time
were determined at baseline and at 2, 6, 12 . 24 and 48 h .
lood samples for platelet aggregation studies and assess-
ment of GPIIb/Ills receptor blockade were drawn at baseline
and at 2, 6, 12 and 48 h . leeding time measurements
obtained using a spring-loaded blade system (Simpla.te) were
performed with a horizontal incision and an occlusive sphyg-
momanometer cuff inflated to a pressure of 40 mm Hg and
were recorded at baseline and at 2, 6, 24 and 48 h . If the
incision continued to bleed for >30 min, the bleeding time
was truncated at this point.
Clinical bleeding events were classified as major, minor
or insignificant using the TIME I study criteria (18) . Trans-
fusions were accounted for by using the method of Lande-
feld et al. (19) (1 U of transfused packed red blood cells =
I g/dl of hemoglobin = 3 hematocrit U) .
In vitro platelet aggregation and GPIIbIIlIa receptor stud-
ies. Platelet aggregation studies and m7E3 Fab binding site
determinations were performed in patients enrolled at three
participating centers . lood was collected in tubes contain-
ing sodium citrate. Platelet-rich plasma was prepared by
centrifugation at 800 x g for 3 to 4 min. Aggregations was
determined in response to 2, 5, and 20 tmollliter adenosine
diphosphate in either a io/Data PAP-4 or CHRONOLOG
~.jgregometer. Each determination of platelet aggregation
was quantified as the maximal change in light transmission
that occurred within 5 min after the addition of adenosine
diphosphate. Aggregation results obtained in samples after
m7E3 Fab administration were expressed as a percent of the
pre-m7E3 Fab injection measurement.
The number of unoccupied GPllb/Illa binding sites on
platelets before and after m7E3 Fab treatment was estimated
by a radiometric method . The basis of this assay is the ex
vivo binding of iodine-125 (' 251)-labeled m7E3 Fab IgG to
platelets. The percent of GPIIb/IIIa receptors that were
blocked in vivo by m7E3 Fab was calculated as 100% x
(A - )/A, where A and  correspond to the number of
molecules of 125 I-labeled m7E3 Fab IgG bound per platelet in
the pre- and post-m7E3 Fab samples, respectively .
Follow-up. All patients underwent clinical follow-up, in-
cluding a physical examination by the investigator at 4
weeks. Platelet counts and determinations of human anti-
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murine antibody were drawn at 2, 4, 6 and 10 weeks . The
presence of human anti-murine antibody was evaluated
using a modification of a previously published solid-phase
enzyme-linked immunosorbent assay (ELISA) in which bio-
tinylated m7E3 Fab was immobilized to solid-phase strept-
avidin in microtiter wells (15). Postinjection samples with an
optical density that exceeded 0.4 and that was two times
greater than the preinjection sample optical density were
considered potentially positive . To be considered positive,
these samples required confirmation of specificity by neu-
tralization of the ELISA activity with solution phase m7E3
Fab.
Statistical methods . ecause bleeding time measure-
ments were truncated, a censored regression model was
used to analyze the association between bleeding events and
bleeding times (20) . This analysis used the occurrence of a
major or minor bleeding event within 5 days after m7E3 Fab
injection and the first postinjection bleeding time (2 h after
the m7E3 Fab bolus) . The significance level of the analysis
was also reanalyzed and confirmed using nonparametric
survival analysis techniques . The censored regression anal-
ysis was chosen because the results are easily interpretable ;
it provides an estimate of the mean difference in bleeding
time in patients with and without bleeding events, and
confidence intervals around the mean difference are readily
constructed . ecause of the small number of patients in the
control group, confidence limits for proportions were not
calculated .
Results
Demographics . aseline clinical characteristics of pa-
tients in the study are shown in Table 2 .
Platelet function. Results of GPIIb/Illa binding site as-
says are shown in Figure 1 . lockade of GPIIb/IIIa receptors
was maximal in the 2-h blood sample . At the two highest
Table
2
. aseline Clinical Data OIL Control and m7E3
Fab-Treated Patients
383
*Includes only patients undergoing cardiac catheterization (9 control
subjects
. 34 m7E3 Fab-treated patients)
. Unless otherwise indicated
. data
shown are mean value t SD
. M1= myocardial infarction ; rt-PA = recombi-
nant tissue-type plasminogen activator
.
m7E3 Fab
Group
(n = 60)
Control
Group
(n = 101
Age (yr)
54 ± 9 55 1- 10
Time to rt-PA (h)
2 .9 ± 1 .7
3 .7 ± 1 .5
Weight (kg)
83 ± 15
75 ± 11
Fibrinogen pre-m7E3 Fab (mgldll 301
linterquartile range)
(178-356)
Male (%)
74
70
Anterior MI 1%)
35
56
While (%)
88
90
Nonwhite (%)
12
10
Multivessel disease' (`70) 60
44
384
	
KLEIMAN ET AL .
m7E3 FA IN MYOCARDIAL INFARCTION
100
eo
60
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0
-20
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olus Dose m7E9 Fab
(m9ft)
0.10 0 .15 0.20
0.25
Figure 1
. Percent of glycoprotein IIb/iila receptors blocked after
the bolus dose of the murine-derived monoclonal antibody 7E3 Fab
(m7E3 Fab). Solid circles represent the mean values for each dose .
doses of m7E3 Fab, the number of available receptors
returned to approximately 50% of baseline at 24 h . Platelet
aggregation in response to 20 p.mol/liter adenosine diphos-
phate is shown in Figure 2. Maximal platelet inhibition
occurred most consistently at 0 .25 mg/kg, with a peak effect
seen in the blood sample drawn at 2 h. Aggregation returned
to approximately 50% of baseline at 6 h and nearly com-
pletely to baseline by 24 h. The results of bleeding time
determinations are shown in Table 3 . leeding time was
maximal at 2 h and returned toward baseline at 24 h,
although more slowly than did the measures of platelet
aggregation.
leeding. lood product transfusions were required in 12
(20%) of 60 patients treated with m7E3 Fab compared with 4
(40%) of 10 control patients. Half of these transfusions
among patients receiving m7E3 Fab were associated with
coronary artery bypass surgery, compared with one of four
Flgure 2. Inhibition of in vitro platelet aggregation to 20 pmol/liter
adenosine diphosphate after the bolus dose of the murine-derived
monoclonal antibody 7E3 Fab (m7E3 Fab). Solid circles represent
the mean value for each dose. Ordinate represents the percent of
baseline value .
150
100
50
a
Control
0.10
0
.15
0
.20
0.25
olus Dose m7E3 Fab (mg,kg)
Table 3. leeding Times in Control Patients and m7E3
Fab-Treated Patients
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(2 .5 to 22.2)
(4
.5 to 15 .0) (5 .0 to (4 .0 to (1 .0 to
14 .1) 27 .0) 30.0)
Values shown are mean bleeding times in minutes at each time after
injection. Interquartile ranges are shown in parentheses .
transfusions in the control group . The changes in hemoglo-
bin, hematocrit and platelet count at 24 h in each dose group
are shown in Table 4. Mean changes were not different for
any of the four dose groups and were not different between
the group receiving m7E3 Fab and the control group .
The number of patients with clinical bleeding events is
shown in Table 5, and the actual events are summarized in
Table 6 . Five of 10 (50%) control patients and 15 of 60 (25%)
m7E3 Fab-treated patients had major hemorrhages during
hospitalization. Of the 20 patients developing a major hem-
orrhagic event, 11 (55%) were related to an invasive proce-
dure, S of which were associated with coronary artery
bypass surgery (1 control subject, 7 m7E3 Fab-treated
patients) . Events not associated with bypass surgery oc-
curred at a median of 9.5 days (range 1 .4 to 21 .2) after rt-PA
administration in control patients and at a median of 1 .5 days
(range 0 to 16.5) after m7E3 Fab administration in the active
treatment group . In addition, 13 (22%) m7E3 Fab-treated
patients and I control patient experienced minor bleeding .
There was no significant correlation between bleeding
events and bleeding times (p = 0 .94) . The median bleeding
time for patients with bleeding events was 0.2 min less (95%
confidence interval -5 .9 to 5 .5 min) than in patients without
bleeding events .
Thrombocytopenic events. Thrombocytopenia occurred
in seven m7E3 Fab-treated patients. Two of the episodes
occurred before filtration of the antibody and the new
dosing regimen were implemented . In the first patient, a
50-year old man, the platelet count reached a nadir of
12,000/mm3 30 min after he received 0 .20 mg/kg of m7E3 Fab
at 15 h after rt-PA . The patient was treated with prednisone .
y day 4, the platelet count had risen to 100,000/mm 3 and
reached 263,000/mm3 on day 7. Peripheral smears of blood
collected in a tube containing EDTA revealed platelet
clumps, whereas those fixed directly in formalin did not.
m7E3 Fab Dose (mg/kg)
Control
Group
(n - 10)
0.1
(n = 5)
0.15
(n = 13)
0 .2
(n = 22)
0 .25
(n = 20)
aseline 8.2 6 .3 8 .5
7.5 4.5
(3 .1 to 11 .0) (3 .0 to 17.8) (6.0 to (3 .0 to (2 .01o
23 .0) 30.0) 21 .0)
2 h 10.4
10 .0 13 .0 15 .8 16 .6
(6 .6 to 21 .8) (6.5 to 16 .0) (7.4 to (3 .0 to (3 .4 to
30 .0) 30
.0) 30.0)
6 h
11 .5 9 .5 14 .0 14 .0 12 .5
(3
.6 to 18.8) (6.8 to 13 .5) (5 .01o (7 .5 to (4 .5 to
24 .3) 30.0) 30.0)
24h 8 .8 9.5 8 .5 9.5 8.5
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Table 4
. Changes in Hemoglobin, Hematocrit and Platelet Count From aseline to 24 Hours After
m7E3 Fab
Hemoglobin (gldl)
	
-1.7 -1 .7
f-1 .3 to -4.1) (-0.1 to -3.6)
Hematocrit 1%)
-6
.4 -5 .7
(-3 .3 to -13 .31
(-0
.5 to -11
.0)
Platelets (% change) -12 -10
(-2 to -38 (-31o -44)
This finding suggested the possibility of EDTA-related in
vitro clumping and pseudothrombocytopenia (21) contribut-
ing at least in part to the low platelet count .
In the second patient, a 74-year old woman, m7E3 Fab,
0.20 mg/kg, was given 15 h after the start of the rt-PA infusion .
Two hours after m7E3 Fab was given, the patient's platelet
count had decreased to 50% of baseline value . Twelve hours
after m7E3 Fab, the platelet count reached a nadir of
9,0001mm3 . The patient underwent transfusion with 6 U of
platelets, and over the next 24 h the platelet count ranged from
94.000 to 74.0001mm3. Two days later, an additional 8 U of
platelets was given, and heparin was discontinued . On day 12,
the platelet count was 280,000/mm 3 .
Five additional patients (one control subject 110 17b] four
m7E3 Fab-treated patients [7%]) had milder thrombocyto-
penia after the institution of filtration . In one patient, this
ev.-nt was noted in the interval between rt-?A and m7E3 Fab
administration; in two patients, thrombocytopenia was noted
immediately after aortocoronary bypass surgery, which was
performed before hospital discharge ; in one patient, a decrease
in platelet count occurred 24 h after intraaortic balloon pump
placement, and in one patient, thrombocytopenia was noted
after 12 days of heparin therapy .
Clinical cardiac events. Table 7 shows the number of
patients in each group with recurrent ischemic events after
m7E3 Fab administration. Although the incidence of definite
recurrent ischemic events was similar in both control and
m7E3 Fab-treated patients (2 of 10 vs. 8 of 60, respectively),
only 4 (9.5%) of 42 patients receiving the two highest doses
of m7E3 Fab (0.20 and 0.25 mg/kg) had ischemic events .
Table 5. leeding Events by Dose of m7E3 Fab
Valaes shown are numberorevent% .
m7E3 Fab Duse (mg/kgo
Control Group 0 .1
0.15 0 .20
0.25
In = 10)
(n = 51 In = 13 ; (n = 22p
In = 20)
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Values shown are mean changes
; interquartile ranges are shown in parentheses .
-1 .8 -2 .3
-2 .3
(0.5 to -5
.2) (0 .510 -4 .8) (0.7 to -5.2)
-6 .0 -5 .8
-6.2
111 .1 to -15 .3) (-2 .3 to -15 .01
(2
.0 to -15.7)
-7
-18 -1 .8
(29 to -50)
(110- .51) (4 to -72)
There was one death in the trial . It occurred in a 59-year
old man who presented within 3 h of symptoms of an anterior
myocardial infarction with transient right bundle branch
block and left anterior fascicular block and who received
0.20 mg/kg of m7E3 Fab 6 h after treatment with rt-PA .
Coronary angiography revealed three-vessel coronary artery
disease and moderate left ventricular dysfunction. He was
found dead in bed 9 days after his infarction while awaiting
bypass surgery . An ambulatory ECG monitor that he was
wearing at the time of death revealed ventricular fibrillation
without preceding ischemic ST segment shifts .
Angiographic findings. Coronary angiography was per-
formed after rt-PA administration in nine control patients at
a median of 121 h (range 3 to 356) and in 34 patients treated
with m7E3 Fab at a median of 129 h (range 6 to 292) after
receiving rt-PA . Anterograde flow (TIM] grade 2 or 3) was
present in 5 (56%) of 9 patients in the control group, 3 of 4
patients receiving 0.1 mg/kg of m7E3 Fab, 6 of 7 patients
receiving 0 .15 mg/kg, 9 of 10 receiving 0 .2 mg/kg and 16 of 16
patients receiving 0 .25 mg/kg m7E3 Fab. Thus, the infarct-
related vessel was patent at angiography in 34 (92%) of 37
patients receiving m7E3 Fab.
Neurologic events. There were no intracranial hemor-
rhages. One patient experienced slurred speech for approx-
imately 20 min, 12 days after receiving m7E3 Fab . Computed
tomographic scanning was not performed .
Immunolagic response. No episodes of anaphylaxis or se-
rum sickness occurred as a result of m7E3 Fab administration .
Of the 60 patients given an iejection of m7E3 Fab, 56 had
plasma samples that could be evaluated for the development of
immune responses. Of the 56 patients who could be evaluated
for human anti-murine antibody responses, 29 (52%) had
positive serum human anti-murine antibody responses. Im-
mune responses were primarily of the IgG isotype .
Discussion
Platelet aggregation clearly pays a role in intraarterial
thrombosis and in its recurrence after successful thrombo-
lytic therapy (4,2: .25) .
Pathologic studies of patients who
have died with totally occluued coronary arteries after
thrombolytic therapy have consistently revealed platelet-
m7E3 Fab Dose (mgfkg)
Type of
Event
Control
Group
(n = ID)
0.1
(n = 5)
0.15
(n = 13)
0.20
(n = 22)
0 .25
(n = 20)
Total
Inlracranial 0 0 0 0
0 0
Major 5 1 3 4
7 20
Minor 1 0 2
4 7 14
Total 6 1
8 14 14
34
"Intervals to m7E3 Fab dosing and to occurrence of bleeding events were recorded from the time of recombinant tissue-type plasminogen activato
administration. CAG = coronary artery bypass graft surgery-associated bleeding
; GI = gastrointestinal;
II
lict = decrease in hemalocrit
; N = no; No source = ru
site for bleeding evident on physical examination
.
rich and fibrin-poor thrombi at the site of plaque rupture in
the infarct-related coronary artery (4) . However, the safety
of profoundly inhibiting platelet aggregation after thrombol-
ysis has been a matter of concern . Although some investi-
gators (5,7,26-29) have shown that thrombolytic drugs, as
well as high levels of plasmin or thrombin, increase platelet
aggregability ; others (30-32) have shown that platelet aggre-
gability in vitro decreases after thrombolysis and that some
agents can cause disaggregation of platelets . An increase in
thromboxane A2 metabolites has been reported in patients
after administration of both streptokinase and rt-PA (26,27) .
Conversely, prolongation of the bleeding time has been
reported it, same patients receiving the combination of
heparin and rt-PA, especially with the coadministration of
aspirin, and in one study, prolonged bleeding times corre-
lated with an increased frequency of spontaneous bleeding
events (33) .
Studies of less potent platelet-inhibiting agents in patients
undergoing thrombolysis have demonstrated a beneficial
effect of this mode of conjunctive therapy . Sharma et al . (34;
Table 7. Clinical Ischemic Events in the m7E3 Fab
Treatment Groups*
'An additional 2 patients (20%) in the control group had a clinical isebemic
event
. Values shown are number of events. n-PA
= recombinant tissue-type
plasminogen activator.
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Table 6.
Major and Minor leeding Events
m7E3 Fab Dose
Interval
Received Time to
(mglkg)
(h)*
Site I Het Transfusion Event (dal
Major bleeding events
Control patients
No source 21 .8 Yes 5 .0
Control patients
No source
17 .3
No
11.8
Control patients
Hematoma
21 .2
Yes
1 .4
Control patients
No source 22 .8 Yes 21 .2
Control patients
- Femoral hematoma. CAG 34 .4 Yes 9 .5
0 .1
12 G1 17
.5
Yes 3.0
0.15
3 Gingival
15 .3 Yes 1
.0
0 .15 6 CAG
18 .0 Yes 2 .2
0.15
6 CAG 19.1 No 4.1
0.20
3 CAG 27
.9
Yes 9 .3
0.20
6 Femoral hematoma
23.4
Yes
16
.5
0.20 12 Epistaxis
15.0
No
1
.1
0.20 12
Hematoma 18.2 No 2.0
0
.25
6 CAG 27.3 Yes 8.0
0
.25
6 CAG 24.9 Yes 10.0
0.25 12 CAG 28.5 Yes 26.2
0.25 12 CAG
21 .0
Yes
9
.9
0.25 12
Femoral hematoma 22.4
Yes
4
.7
0.25 12 Of 15 .7 Yes 1 .0
0.25 12 Femoral hematoma 26.4 Yes 0
Minor bleeding events
Control patients
- Epistaxis, gingival 9.3
No 10.1
0.15 6 Hematuria 10.1
No
3
.1
0.15 12 Epistaxis 8 .8 No 110
0.20 6 Femoral hemaroma 9.3 No 12 .7
0.20 6
No source 12 .3 No 1 .1
0.20 12 No source 11 .1
No 1 .1
0.20 12 No source 12 .9 No 9 .5
0
.25 3 No source 11 .8 No 1
.7
0.25
3 CAO 13 .6 No 5
.1
0.25 3
No source 14 .0 No 8 .9
0
.2$ 6 Femoral hematoma 12 .1
No 4 .5
0.25 6
No source 13 .3
No 1 .0
0.25
12 No source 12.8 No 19.6
0.25 12 Hemoptysis
11 .2 No
2 .0
Rows From
Start of control
n-PA Group
Infusion
(n = 10)
m7E3 Fab Dose (mglkg)
0
.1
(n = 5)
0.15
(n = 13)
0 .20
(n = 22)
0.25
(n = 20)
Total
(n = 60)
IS
2 I
0 3 6
6
- I I
0 2
3 - 0 0
0 0
Total
2 2 I 3
8
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showed that intracoronary administration of prostaglandin
E I to patients receiving intracoronary streptokinase de-
creased the time required to achieve lysis and lowered the
rate of reocclusion ; however, in the Thrombolysis and
Angioplasty in Myocardial Infarction (TAMI) Phase 4 study,
the administration of prostacyclin with rt-PA did not in-
crease vessel patency at 90 min (35) . This finding may have
been explained by poor tolerance of the side effects of
prostacyclin as well as by an increased rate of catabolism of
rt-PA secondary to increased splanchnic blood flow (36) . No
increase in hemorrhagic events was noted . In the ISIS-2
study, the combination of aspirin and streptokinase led to a
50% decrease in the rate of reinfarction as well as a 17%
decrease in mortality compared with therapy with streptoki-
nase alone . These benefits occurred at the cost of an 0 .3%
excess in transfusions (9) .
The results of the present study indicate that after treat-
ment with rt-PA, aspirin and heparin, doses of m7E3 Fab
producing marked inhibition of platelet aggregation and
prolongation of bleeding time well in excess of that obtained
with aspirin alone appear to be well tolerated . The changes
in hemoglobin, the frequency of major bleeding events and
the number of transfusions required were comparable be-
tween control and m7E3 Fab-treated patients . The major
bleeding events in m7E3 Fab-treated patients occurred at a
time when bleeding time and measurable indexes of platelet
function had returned to baseline . If one excludes transfu-
sions given during the course of coronary artery bypass
surgery, then 11% (6 of 54) of patients treated with m7E3
Fab required transfusion compared with 33% (3 of 9) of
control patients. Thus, there was no evidence of increased
blood loss as a result of m7E3 Fab administration, and the
degree of platelet inhibition, as evidenced by the bleeding
time, was not related to the likelihood of bleeding .
Severe thrombocytopenia occurred within the 1st day in
two of the first four patients treated . After alterations were
made in the handling and the technical aspects of adminis-
tering m7E3 Fab, this probiem did not recur in the remaining
56 patients receiving active drug . Although a role for m7E3
Fab causing less severe thrombocytopenia in four patients
cannot be excluded, the time course of these events was
considerably different . The decrease in platelet count either
preceded m7E3 Fab administration or occurred days later,
after GPIIb/IIIa receptors had become available and after
the circulating platelet pool would have been expected to
have been renewed . In three cases, the decrease in platelet
count was associated with an invasive procedure (intraaortic
balloon pump or coronary artery bypass surgery) for which
thrombocytopenia is a recognized complication .
Although this study was not designed primarily to exam-
ine the efficacy of r.^E3 Fab, the frequency of recurrent
ischemic events was surprisingly low in the patients who
were treated at the highest doses of m7E3 Fab (i .e., those
doses that consistently produced maximal platelet inhibi-
tion) . Although the power of this observation is limited, it is
noteworthy because these patients were treated initially with
KLEIMAN ET AL .
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a lower dose of heparin (2,000 U bolus followed by an
infusion of 800 U/h) than is conventionally used with rt-PA
and might have been expected to be at higher risk of
reocclusion and recurrent ischemia . Several clinical studies
have emphasized the importance of vigorous heparin ther-
apy for maintaining arterial patency after treatment with
rt-PA (37-40) . In this study, arterial patency was present in
92% of patients studied, despite the use of a low dose of
heparin. ecause thrombin can promote thrombus formation
through its effects on both fibrinogen and platelets, and
because the extent of thrombin inhibition required in vivo to
prevent the action of thrombin through these two pathways
is not yet clear, the current study raises the possibility that
prevention of reocclusion can be achieved after thromboly-
sis with lower heparin doses if platelet aggregation is inhib-
ited by simultaneous GPIIb/IIIa receptor blockade . This
(+id'erence in heparin dosing may have contributed to the
_safety of m7E3 Fab .
The relative importance of thrombin inhibition versus
GPIIb/llla blockade in the prevention of arterial thrombosis
after successful thrombolysis is not yet delineated . Throm-
bin is an extremely potent agonist of platelet aggregation,
particularly after thrombolysis (29), whereas the interaction
of fibrinogen with GPIIb/IIIa is the final common step in
platelet aggregation regardless of the stimulus . Although one
recent animal experiment indicated that direct thrombin
inhibition was superior to GPIIb/IIIa blockade (41), the
GPIIb/IIIa blocking agent used in that experiment was an
Arg-Gly-Asp (RGD)-sequence peptide that may behave dif-
ferently than m7E3 Fab. In fact, a similar RGD-containing
peptide has been shown in one study to have paradoxic
GPIIb/IIIa-activating properties (42) . A recent preliminary
report directly compared the m7E3 F(ab') 2Irt-PA combina-
tion with rt-PA combined with a short infusion of the potent
thrombin inhibitor hirudin (43) in a dog model of coronary
thrombosis . In that study, reocclusion and mortality were
prevented by m7E3 Fab but not by hirudin. However, in a
previous study of patients with unstable angina treated with
lower doses of the F(ab') 2 fragment of m7E3 Fab but with
neither heparin nor aspirin (15), ischemic events were abol-
ished during the period of platelet suppression, but a high
frequency of recurrent ischemia was reported after the
return of platelet function to baseline values . This phenom-
enon was not seen in the present study and may have been
related to the higher doses of the smaller 7E3 Fab molecule
used in this study or by the addition of aspirin and heparin .
The current study is unique in two aspects
. It is the first
to examine the combination of a thrombolytic drug with a
receptor-specific platelet antagonist in patients with myocar-
dial infarction, and it is also the first to examine the combi-
nation of a thrombolytic drug with a platelet-inhibiting agent
that acts through a mechanism other than the thromboxane
pathway for platele ` aggregation
. Although the study is
small, and the design was not randomized, it is clear that the
combination of a thrombolytic drug, heparin, aspirin and a
potent GPIIb/IIIa antagonist can be administered with a
ap
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